1. Signaling Pathways
  2. GPCR/G Protein
    Immunology/Inflammation
  3. CCR
  4. CCR8 Isoform
  5. CCR8 Antagonist

CCR8 Antagonist

CCR8 Antagonists (5):

Cat. No. Product Name Effect Purity
  • HY-119217
    AZ084
    Antagonist 99.65%
    AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a Ki of 0.9 nM. Has potential to treat asthma. AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer.
  • HY-122219
    R243
    Antagonist 98.09%
    R243 is a potent and selective CCR8 antagonist. R243 inhibits CCL1/CCR8 interaction and inhibits CCR8 signaling and chemotaxis. R243 has antinociceptive and anti-inflammatory effects.
  • HY-144197
    CCR8 antagonist 1
    Antagonist 99.50%
    CCR8 antagonist 1 (Compound 15) is a potente human CCR8 antagonist with a Ki of 1.6 nM. CCR8 antagonist 1 has high safety and metabolic stability. CCR8 antagonist 1 can be used to study diseases such as asthma and multiple sclerosis.
  • HY-153669
    SB-649701
    Antagonist
    SB-649701 is a potent human CCR8 antagonist, with a pIC50 of 7.7. AZ084 can be used for the research of asthma.
  • HY-160647
    CCR8 antagonist 3
    Antagonist
    CCR8 antagonist 3 (compound 2) is a CCR8 antagonist with an IC50 value of 0.062 µM. CCR8 antagonist 3 shows human microsomal stability.